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AbstrACt
Objective Electronic healthcare databases (EHDs) are 
useful tools for drug development and safety evaluation 
but their heterogeneity of structure, validity and access 
across Europe complicates the conduct of multidatabase 
studies. In this paper, we provide insight into available 
EHDs to support regulatory decisions on medicines.
Methods EHDs were identified from publicly available 
information from the European Network of Centres for 
Pharmacoepidemiology and Pharmacovigilance resources 
database, textbooks and web-based searches. Databases 
were selected using criteria related to accessibility, 
longitudinal dimension, recording of exposure and 
outcomes, and generalisability. Extracted information was 
verified with the database owners.
results A total of 34 EHDs were selected after applying 
key criteria relevant for regulatory purposes. The most 
represented regions were Northern, Central and Western 
Europe. The most frequent types of data source were 
electronic medical records (44.1%) and record linkage 
systems (29.4%). The median number of patients 
registered in the 34 data sources was 5 million (range 
0.07–15 million) while the median time covered by 
a database was 18.5 years. Paediatric patients were 
included in 32 databases (94%). Completeness of 
information on drug exposure was variable. Published 
validation studies were found for only 17 databases (50%). 
Some level of access exists for 25 databases (73.5%), and 
23 databases (67.6%) can be linked through a personal 
identification number to other databases with parent–child 
linkage possible in 7 (21%) databases. Eight databases 
(23.5%) were already transformed or were in the process 
of being transformed into a common data model that could 
facilitate multidatabase studies.
Conclusion A Few European databases meet minimal 
regulatory requirements and are readily available to be used 
in a regulatory context. Accessibility and validity information 
of the included information needs to be improved. This study 
confirmed the fragmentation, heterogeneity and lack of 
transparency existing in many European EHDs.
IntrOduCtIOn
The European Union (EU) medicines regula-
tory network has responsibility for protecting 
patients by ensuring continuous evaluation 
of the safety of authorised medicines. At the 
core of such review is the scientific assess-
ment of all available evidence including 
relevant information from the literature, 
results from non-clinical studies, randomised 
clinical trials, observational studies, sponta-
neous reports and results of other available 
research. A way to collect more information 
about a medicine’s safety postmarketing 
is by means of postauthorisation safety 
studies (PASS).1 PASS may be imposed on a 
marketing authorisation holder by a regula-
tory authority or conducted by the company 
to address a safety concern or evaluate the 
effectiveness of risk-minimisation measures 
aimed at reducing the occurrence or severity 
of an adverse reaction.2 3 
Secondary use of routinely collected data 
from electronic healthcare databases (EHDs) 
is often used in such studies because it is 
usually faster and cheaper than primary data 
collection.
A review of pharmaceutical industry-spon-
sored studies evaluating the effectiveness of 
risk-minimisation measures submitted to 
the European Medicines Agency (EMA) for 
strengths and limitations of this study
 ► Data extraction was based on information pro-
vided by database owners and publicly available 
information.
 ► Incomplete data extraction cannot be excluded, es-
pecially for very small databases with few published 
outputs.
 ► Validation of the data source was evaluated indi-
rectly through the validation studies reported by the 
database owners.
 ► The inventory was endorsed by an expert work-
ing group of the European Network of Centres for 
Pharmacoepidemiology and Pharmacovigilance (the 
ENCePP Working Group ‘Data Sources’).
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cardiovascular, endocrinology or metabolic drugs autho-
rised between 1995 and 2015 found that EHDs were used 
in 53% of studies evaluating routine risk-minimisation 
measures and in 31% of studies evaluating additional 
risk-minimisation measures.4 A second review of 189 PASS 
assessed by the EMA between 2012 and 2015 and regis-
tered in the EU electronic Register of Post-Authorisation 
Studies (EU PAS Register) reported that secondary use of 
routinely collected data was found in 33.3% of PASS, and 
58% among these leveraged electronic health records 
(EHRs).5 A third review of a different set of studies regis-
tered in the EU PAS Register as of December 2016 found 
that 117 studies (37%) used an existing claims or elec-
tronic medical records database.6 A fourth review evalu-
ating studies which measured the impact of regulatory 
interventions found that claims databases were used in 
45% of studies, while EHRs were used in 22% of them, 
the latter being the most used type of data sources for 
such studies.7 The frequent use of EHDs in observational 
studies was also reported in a wider context in a review of 
the abstracts of presentations made at the International 
Conference for Pharmacoepidemiology: 53% (in 2000) 
and 51% (in 2005) of submitted EU pharmacoepidemio-
logical studies were conducted using automated general 
practice, pharmacy or claims data.8
The fact that between 30% and 50% of observational 
postauthorisation studies use EHDs as their main data 
source reflects the importance of these data sources to 
support regulatory decision-making.1 9 On the other 
hand, the use of EHDs in preauthorisation research is 
currently limited and mostly focused on providing histor-
ical control data or understanding the natural history of 
the disease.
As regulatory decisions based on EHDs may have a 
considerable impact on public health, the quality of 
the information, the validity and reproducibility of the 
derived results require close attention, especially when 
combining data from several data sources or when the 
original data is transformed before analysis.10–12 It has 
been emphasised that the same level of scientific rigour 
should be employed irrespective of the study design 
and data source to be used, and that the strengths and 
weaknesses of each data source should be considered.13 
The speed at which the results could be generated is 
an additional important consideration, particularly for 
regulatory purpose.9 14 15 By considering the character-
istics of the data sources and the research objectives to 
be addressed, the investigators should be able to choose 
the most appropriate resource(s) to address the question 
at hand. However, while some authors provide a detailed 
description of the databases used in their study,16–19 in 
other cases the description is often incomplete, and a 
justification for their choice in the context of alterna-
tive data sources is rarely provided.18 The International 
Society of Pharmacoepidemiology has developed guide-
lines to support the selection and use of data sources for 
observational research by highlighting potential limita-
tions of databases and recommending testing procedures. 
The guidelines also provide a checklist covering six 
areas: database selection, use of multiple data resources, 
extraction and analysis of the study population, privacy 
and security, quality and validation procedures and docu-
mentation.20 The availability of an inventory of European 
databases describing the main characteristics, conditions 
of access and validation performed would support inves-
tigators to identify databases suitable for their research 
question. Moreover, knowledge of the characteristics of 
the data sources used in a postauthorisation study would 
enhance regulators’ confidence in the evidence derived 
from such data and ultimately in the usefulness of the 
study in the decision-making process.21 22
The main objective of this study is to provide an inven-
tory of EHDs and describe their key characteristics and 
availability with the aim to support stakeholders in their 
choice of the data source when conducting a postauthori-
sation study.
MethOds
Identification of ehds
As a first step, we identified existing EHDs in Europe by 
screening the following sources: the European Network 
of Centres for Pharmacoepidemiology and Pharma-
covigilance (ENCePP) resources database,21 web-based 
search engines,22 textbooks on clinical pharmacoepide-
miology,23 24 publicly available inventories created for 
European Commission-funded research projects and 
databases used in EMA-funded postauthorisation studies.
As a second step, data sources were included in the 
inventory based on the following regulatory relevant 
criteria: the data are available to regulatory authorities 
or to third parties for research purposes; the database 
contains information on both drug exposure and health 
outcomes and is not disease or product specific; there is 
longitudinal data capture. Provision of relevant data for 
benefit–risk decision-making was one of the key criteria 
for selecting studies meeting regulatory requirements.
Prescription-only databases were excluded because they 
cannot be used for aetiological studies in the absence of 
the outcome recording. Product-specific or disease-spe-
cific registries were considered out of scope as they create 
cohorts of patients whose entry is defined either by expo-
sure to a product or by occurrence of a disease or health 
outcome.25
Product-specific registries are frequently used for the 
benefit–risk monitoring of specific products, however 
they rarely cover a wide range of medicines and health 
conditions and have a narrow scope. Databases where the 
data collection ceased and the historical data were not 
accessible were also excluded.
data extraction and classification
For each database, publicly available information (on the 
databases’ websites or in publications) was supplemented 
by contacting data source owners in writing. A total of 
82% database owners responded. Teleconferences with 
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seven database owners were conducted to clarify some of 
the information provided.
The information was extracted by six EMA reviewers 
(AP, KP, PMG, DM, JS, AC), and the entries for each 
database were cross-checked for consistency by a second 
reviewer. Uncertainties about the classification of any 
variable were resolved through discussion.
The data sources were classified in three categories 
according to their structure, purpose and type of data: 
electronic medical records, claims databases and health-
care record linkage systems (eg, several databases are 
linked to form a complete database).
The different population registries within the same 
country were considered as a single national EHD if they 
could (and are routinely used as such) be linked using 
a unique identification number (eg, in Nordic countries 
and in Scotland).The size of the data source was quanti-
fied by the cumulative number of patients included (both 
total and active patients) and number of years since the 
initiation of data collection in the database.
Data collected in the following categories was also 
recorded: demographic information (age and gender of 
each individual), information on prescribed or dispensed 
medicines (including name, dose, duration, route of 
administration and therapeutic indication), immunisa-
tions, diagnosis data and referrals for laboratory investi-
gations, imaging and other procedures. Information of 
laboratory tests results was not collected.
Availability of validation studies
Database owners were asked to report validation studies 
which they were aware of for their database. Studies 
published up to September 2016 were included. For the 
purpose of this study, a validation study was defined as 
any study published in a peer-reviewed journal that aimed 
to validate the information available on an outcome or 
exposure in comparison with gold standard information, 
usually the patients’ original health records as reviewed 
by a medical professional or the same information 
captured by another database for a different purpose. 
For example, a study in 2012 compared cancer records 
in a general practitioners’ database, hospital records and 
cancer registries and found considerable discrepancies in 
cancer recording between these different data sources.26
Accessibility
The accessibility of databases for research purposes was 
classified in four categories: no access, indirect access 
through the database owner or a third party, direct access 
restricted to specific datasets and direct access to the full 
dataset.
Coding of database characteristics for usefulness for 
medicines benefit–risk evaluation
Instead of evaluating the quality of each database, we 
aimed to assist in the selection of databases by imple-
menting a coding process that identifies the data 
sources considered to provide sufficient information to 
contribute to regulatory questions on the benefit–risk 
evaluation of medicines. For this purpose, the following 
domains were included in the coding process: extent of 
data capture of study variables, size of data source, quality 
and validity of information, accessibility, potential for 
linkage and existing process in place to convert the data 
into a common data model (CDM) (figure 1). A CDM 
provides a common representation and architecture of 
the data across multiple databases, thus enabling the stan-
dardisation of administrative and clinical information 
and allowing the use of common analytical tools.27
The ENCePP Working Group ‘Data Sources’9 reviewed 
an initial version of the inventory with the description of 
databases and endorsed the final inventory.
Patient involvement statement
This descriptive analysis did not involve any patients.
results
General overview
The initial search generated a list of 77 potential data 
sources. After merging the national registries into a single 
entry and applying the exclusion criteria, 34 of them were 
retained in the final inventory (figure 2). Table 1 provides 
a list of these 34 databases and the complete information 
is provided in the online supplementary material.
The most frequent types of data source identified were 
electronic medical records (n=15, 44.1%) followed by 
record linkage systems (n=10, 29.4%) and claims data-
bases (n=9, 26.5%). In terms of the type of care covered, 
mixed-care settings (primary and secondary care) were 
most common (n=17, 50%), followed by primary care 
databases (n=11, 32.3%) (table 2). The median number 
of patients followed cumulatively across the 34 data 
sources was 5 million (range 0.07–15 million).
Patient age and gender were recorded in all data 
sources while paediatric patients were included in 32 
databases (94%). The median year for database start 
was 1998, with the oldest database established in 1964 
(the Finnish Hospital Discharge Register). The median 
calendar time covered by a database was 18.5 years (range 
7–53 years). In terms of geographical coverage, 17% of 
databases collect data from Norway, 14% from Finland 
and 10% from Denmark and Italy (figure 3).
Information captured
By definition, all the databases retained in the final inven-
tory contained information about drug exposure (either 
prescribed or dispensed). The completeness of infor-
mation was however variable: 28 databases (82.3%) had 
information about prescribed dose and duration of treat-
ment (either directly recorded or inferred from other 
collected variables); 14 (41.1%) had information about 
route of administration; 20 databases (58.8%) recorded 
the therapeutic indication associated with the prescrip-
tion (either directly recorded or inferred from other 
database elements). Over-the-counter drugs were rarely 
4 Pacurariu A, et al. BMJ Open 2018;8:e023090. doi:10.1136/bmjopen-2018-023090
Open access 
and inconsistently captured in any of the databases while 
vaccinations were captured in 13 databases (38.0%). Data 
on hospital inpatient administered drugs were rarely 
captured (5.8%).
All databases had information about medical events 
(diagnosis) as a prerequisite for inclusion in our inven-
tory. Referrals for laboratory investigations were captured 
in 19 (55.9%) and referrals for imaging or other diag-
nostic procedures were captured in 16 databases (47.1%).
Validation studies
No published validation study was reported for 17 data-
bases (50.0%), while a total of 42 validation studies were 
reported for the other 17 databases, with a median of 
3 validation studies per database (range: 1–25). The 
validation concerned either specific health outcomes 
or prescription information. The most common gold 
standards used for the validation included paper-based 
prescriptions, medical records, death records and peri-
natal deaths obtained from registries or national statis-
tics reports. Some database owners have reported as 
validation studies the validation of prediction algorithms 
for various health outcomes as chronic kidney disease, 
ischaemic stroke and various types of cancers based on 
an estimating the absolute risk of a particular outcome in 
primary care patients with and without symptoms.1 2 It is 
debatable if these are truly validation studies according to 
our definition.
Accessibility and potential for linkage
During selection, one database was excluded due to lack 
of access to third parties. From the 34 included data-
bases, 11 (32.3.4%) offer indirect access to the data-
base for third parties, 6 (17.6%) provide direct access 
to specific datasets and 11 (32.3%) offer direct access 
to the full dataset. The level of access could not be 
identified for 6 EHDs (17.6%). In terms of linkage, 23 
databases (67.6%) could be linked through a unique 
personal identification number (PIN) to other data-
bases containing additional healthcare-related informa-
tion including cause of death registries, hospital data, 
prescription databases and cancer registries. The Nordic 
Figure 1 Coding of the characteristics of electronic healthcare databases available in Europe for the benefit–risk evaluation 
of medicines. The coding system was binary: 0 if information was absent and 1 if it was present. The degree of completion 
for a specific variable was not recorded. An exception to the binary classification was done for the accessibility variable: 0, no 
access; 1, indirect access through database owner or third party; 2, direct access to specific data sources; 3, direct access to 
full data source.
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registries are a good example of extensive linkage 
among different national registries through usage of a 
PIN. Other forms of linkage do exist, for example, in 
order to avoid the use of PIN and preserve anonymity, 
the PHARMO network uses probabilistic linkage based 
on patient birth date, gender and general practitioner 
code. The linkage of a parent with their child (‘parent–
child linkage’), which is useful for studies investigating 
pregnancy exposures and effect on offspring, was avail-
able in seven data sources (20.6%).
Conversion of the database to a CdM
Four (11.7%) databases were already transformed in 
a CDM and four others were in the process of being 
converted to a CDM (the QuintilesIMS Disease Analyser 
France and Germany, the Spanish Information System 
for the Development of Research in Primary Care, the 
Agenzia Regionale di Sanità Tuscany database, The 
Pedianet, the Clinical Practice Research Datalink, the 
Integrated Primary Care Information Database and The 
Health Improvement Network). Seven of these eight 
databases used the Observational Medical Outcomes Part-
nership CDM,27 while the Spanish Information System 
for the Development of Research in Primary Care28 is 
implementing the model used in the Accelerated devel-
opment of vaccine benefit-risk collaboration in Europe 
(ADVANCE) project for vaccine studies.29
dIsCussIOn
A total of 34 European EHDs with potential for use in 
the regulatory environment were included in this study. 
The most frequently represented regions were Northern, 
Central and Western Europe, with a scarcity of data 
sources in Eastern Europe. The most common data 
sources assessed were electronic medical records with 
a mix of primary and secondary care coverage. Most of 
the databases contain outpatient prescribing while inpa-
tient prescribing is very rarely captured. The median 
number of patients registered within the 34 data sources 
was 5 million, and the median calendar time covered 
by a database was 18.5 years. In terms of accessibility, 
24% of databases offered direct access to the full data 
source, with the rest having a somewhat more limited 
access. There are a few similar studies of EHDs available 
in Europe,8 30 but as far as we are aware this is the first 
study taking a regulatory perspective. An analysis of the 
characteristics of postauthorisation studies requested by 
regulators showed that 47% of studies involved secondary 
use of data emphasising the important role of secondary 
data in the regulatory setting. More detailed descriptions 
of database characteristics are provided in electronic 
repositories such as the European Medical Information 
Network (EMIF), the ENCePP resource database and the 
Bridge to Data initiative.21 22 However, existing reposi-
tories are either incomplete, have a limited coverage or 
Figure 2 Flow chart of database selection.
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Table 1 List of data sources retained in the final inventory (by year)
Data source name Country Type Type of care
Start 
date
Finnish National Registries Finland Record linkage system Mixed 1964
Swedish National Registries Sweden Record linkage system Mixed 1970
Danish National and Regional Registries Denmark Record linkage system Mixed 1977
The electronic Data Research and Innovation 
Service
Scotland Record linkage system Mixed 1981
Clinical Practice Research Datalink UK Electronic medical 
records
Primary care 1987
QResearch UK Electronic medical 
records
Primary care 1989
Information System of Parc de Salut del Mar Spain Electronic medical 
records
Primary care 1990
Medicines Monitoring Unit Scotland Scotland Record linkage system Mixed 1990
PHARMO Database Network Netherlands Record linkage system Mixed 1990
QuintilesIMS Disease Analyser Germany Electronic medical 
records
Mixed 1992
Integrated Primary Care Information Database Netherlands Electronic medical 
records
Primary care 1995
Agencia Regionale di Sanita Tuscany database Italy Claims Secondary care 1996
Norwegian Registries Norway Record linkage system Mixed 1997
QuintilesIMS Disease Analyser France Electronic medical 
records
Primary care 1997
Region Emilia Romagna Database Italy Claims Secondary care 1997
Hospital Information System—Lazio Italy Claims Secondary care 1998
Icelandic Registries Iceland Record linkage system Mixed 1998
Pedianet Database Italy Electronic medical 
records
Primary care 1998
Securite Sociale de l'Assurance Maladie France Claims Mixed 1999
Lombardia Health Database Italy Electronic medical 
records
Secondary care 2000
QuintilesIMS Longitudinal Patient Database (LPD) Italy Electronic medical 
records
Primary care 2000
QuintilesIMS LifeLink: Hospital Disease 
Database—Belgium
Belgium Electronic medical 
records
Secondary care 2001
QuintilesIMS LPD Health Search Database France Electronic medical 
records
Mixed 2001
Base de Datos para la Investigación 
Farmacoepidemiológica en Atención Primaria
Spain Electronic medical 
records
Primary care 2002
Caserta Database Italy Claims Primary care 2002
The Health Improvement Network UK Electronic medical 
records
Primary care 2002
German Pharmacoepidemiological Research 
Database
Germany Claims Mixed 2004
Echantillon Généraliste de Bénéficiaires France Claims Mixed 2006
QuintilesIMS LPD Health Search Database 
Longitudinal
Spain Electronic medical 
records
Mixed 2006
The Information System for the Development of 
Research in Primary Care
Spain Electronic medical 
records
Primary care 2006
VEKTIS Netherlands Claims Mixed 2006
Continued
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they require a fee for access, therefore restricting access 
to their information.
This study helps identify databases with key character-
istics as an entry door to further investigate with their 
owner their potential usefulness for a specific study.
Given that different national guidelines and clinical 
practice can generate significant heterogeneity in how 
healthcare is delivered and recorded,31 it is important 
that regulators have access to data from as broad a 
geographical spread as possible. Thus, there is a clear 
need for the development of data sources in EU member 
states which currently either have no data sources or are 
poorly represented.
The data recorded in the databases include some limita-
tions. First, the limited capture of inpatient prescribing 
poses a problem for regulators and investigators since 
many newly approved drugs are specialised drugs, used 
exclusively in secondary care.32 Second, some disease-spe-
cific variables (eg, biomarkers, laboratory tests and 
genetic data) are only exceptionally recorded, and they 
are required more and more often in study protocols. 
High-quality disease registries can to some extent meet 
this need in specific disease areas but they rarely capture 
comedications, comorbidities and adverse reactions. 
Improvements in the quality of inpatient care and in the 
recording of laboratory tests would be of value for epide-
miological investigations on determinants for health 
outcomes, including drug-related safety issues.
With regard to validation, 50% of databases had at 
least one validation study published. Validation should 
normally be done for the data elements collected in every 
study. Publication of validation studies is not an indicator 
of the overall validity of the database but may inform 
researchers on the feasibility to perform study-spe-
cific validation in a database. A repository of validated 
outcomes in specific databases would reduce duplication 
of work. Such a repository should include a clear descrip-
tion of the methodology and limitations of the analysis.
Extending approved adult indications to the paediatric 
population is increasing and according to the European 
Commission's report between 50% and 90% of the medi-
cines currently used in paediatrics have neither been 
tested on nor authorised for use in children.32 Availability 
of real-world data is therefore particularly important for 
this purpose. In our review, we found that 94% of data-
bases have some information about paediatric patients 
but no in-depth analysis of the available information was 
undertaken. A more detailed review of paediatric data-
bases was undertaken by Neubert et al who concluded 
that in Europe, drug utilisation and outcome data are 
available for ~4 million children.33 However, similar to our 
study, the authors highlight that efforts should be made 
to increase availability of inpatient data, a setting where 
the greatest prescribing of novel medicines occurs.33
While validity studies were published for half of the 
databases, van Staa and Klungel15 highlighted that system-
atic measurement of data quality is lacking in most data-
bases. As such and in line with the recommendations of 
Hall et al,20 we encourage data holders to document the 
basic characteristics of their data source and to highlight 
when a change in recording practices occurs.
A new way forward to increase the speed and power of 
multicentres studies is the use of a CDM.34 The advan-
tage of using a CDM is that the transformed databases can 
be more easily integrated for research across a network. 
Although less than one-third of databases were already 
converted or in the process of being converted to a CDM 
in Europe, these figures are likely to change fast due to 
ongoing initiatives such as EMIF35 and the European 
Health Data Network project.36
Access to databases for research purposes can be 
provided at patient level in only a tof databases while the 
remaining ones had more restrictive access policies. We 
therefore fully support the recommendations published 
by other groups that governance models should be in 
place to facilitate data access, data sharing and secondary 
use of research data in health sciences.37
There are multiple challenges to the utilisation of EHDs 
in a regulatory context, particularly in Europe, which go 
beyond the above-mentioned challenges related to the 
characteristics of the specific databases. These include 
fragmentation and lack of interoperability of European 
data sources, inconsistent use of methods to integrate 
and analyse heterogeneous data, lack of systematic and 
Data source name Country Type Type of care
Start 
date
Secure Anonymised Information Linkage Wales Record linkage system Mixed 2007
National Health Fund Poland Claims Mixed 2008
Hospital Treatment Insights UK Record linkage system Secondary care 2010
Table 1 Continued 
Table 2 Distribution of data sources type and type of care 
covered
Type of data source
Primary 
care, %
Secondary 
care, % Mixed, %
Claims 1 (2.9) 3 (8.82) 5 (14.7)
Electronic medical 
records
10 (29.4) 2 (5.9) 3 (8.8)
Record linkage 
system
0 (0) 1 (2.9) 9 (26.5)
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consistent validation of data sources, governance issues 
and privacy concerns. In an attempt to deal with the 
significant heterogeneity across data sources in Europe, 
ENCePP has established a Working Group dedicated to 
facilitating the initiation and conduct of observational 
research using multiple data sources.9 As part of its work, 
the group reviewed ongoing or finalised multidatabase 
drug safety projects of various publicly funded EU proj-
ects which highlighted the heterogeneity of the methods 
used for combining EHR data from multiple databases.3 
Ongoing work of the group is centred around developing 
guidance on conceptual models for multinational and 
multidatabase studies.
Our review has a number of limitations. First, we 
may have missed data sources during the identifica-
tion process. However, we attempted to be as complete 
as possible by incorporating several rounds of database 
identification and review of the inventory by experts, 
including members of the ENCePP Working Group ‘Data 
sources’ and database owners. The difficulties we encoun-
tered when trying to map all the existing EHDs in Europe 
highlight again the need for more comprehensive and 
accessible repositories with EHDs.
Second, we excluded prescription-only databases since 
they cannot be used for aetiological studies even if we 
acknowledge their utility for drug-utilisation studies which 
are very common in the regulatory field. Lastly, validation 
of the primary source data is an important process that 
provides confidence in the results of the analyses,38 and 
this was only evaluated indirectly through the number 
of validation studies reported by the database owners. A 
strength of our study was that data from publicly avail-
able sources was complemented or verified with database 
owners.
There is more work to be done in order to increase trans-
parency and accessibility of existing datasources. Exam-
ples of areas for future development are to develop more 
robust validation measures and increase transparency of 
validated outcomes, to transform databases through a 
CDM to allow faster feasibility assessment and execution 
of studies, and to stimulate creation and access to EHRs 
in Eastern Europe.
COnClusIOn
We have provided a systematic inventory of EHDs avail-
able in Europe that includes a summary evaluation of 
their capability to support regulatory decision-making on 
the benefits and risks of medicines in Europe. Despite the 
wide range of healthcare databases available for epidemi-
ological research in Europe, many of them were excluded 
from the inventory due to the absence of information 
needed for key regulatory activities. The analysis of the 
included databases confirmed the fragmentation, hetero-
geneity and lack of transparency existing in European 
EHDs.
The analysis has focused on population-based EHDs 
allowing conducting causal association studies between 
drug exposure and health outcomes in primary care. Our 
intention is to help the identification of and access to 
relevant existing databases that could be used for public 
health research. Beyond this objective, we consider that 
this inventory may assist clinical epidemiologists inter-
ested in undertaking other investigations such as studying 
the occurrence and determinants of health outcomes in 
a population.
We hope that this inventory should stimulate increased 
transparency and accessibility of other databases in addi-
tion to the development of data sources in Eastern Euro-
pean countries which are currently under-represented.
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